Intercept CRL Likely About OCA-Specific Concerns, Not NASH Endpoints

 
• By Joseph Haas
  
liver
The complete response for OCA may have opened up the NASH race
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Complete Response Letters

More from Product Reviews